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Abstract. A blood-based biomarker to complement the clinical and neuropsychological assessments used to evaluate the risk
of individuals with mild cognitive impairment (MCI) developing Alzheimer’s disease (AD) would be invaluable. Previous pilot
studies by our group identified elevated platelet membrane -secretase activity in patients with AD and MCI, as compared to
controls, and this activity was influenced by membrane cholesterol levels. The present study investigated baseline platelet mem-
brane -secretase activity and cholesterol levels in 97 MCI participants and 85 controls and explored whether these parameters
differed in individuals with stable MCI, as compared to those who subsequently developed AD. To evaluate signal specificity,
-secretase activity assays were conducted in the presence and absence of beta-site amyloid- protein precursor-cleaving enzyme
(BACE) inhibitors. Baseline platelet membrane -secretase activity did not differ significantly in MCI participants, as compared
to controls, and platelet membrane cholesterol levels were significantly lower in the MCI group. The longitudinal study indicated
that the activities inhibited by two different BACE inhibitors did not predict conversion to AD; however, the activity that was
not affected by BACE inhibitors was significantly (40%) higher in individuals with stable MCI, as compared with those who
subsequently developed AD. These findings indicated that further research into the source of this activity could contribute to a
measure facilitating prediction of the risk of conversion from MCI to AD.
Keywords: Amyloid- protein precursor, beta-site amyloid- protein precursor-cleaving enzyme, cognition, dementia, Neu-
ropsychology, protease inhibitor
INTRODUCTION
Mild cognitive impairment (MCI) can be defined
as greater cognitive decline than that expected for an
individual’s age and education level, in the absence
of dementia or impairment of activities of daily liv-
ing (ADLs) [1–2]. In 2004, an international working
group on MCI formulated specific recommendations
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Centre for Public Health, Queen’s University Belfast, Institute
of Clinical Science B, Grosvenor Road, Belfast BT12 6BA,
N. Ireland. Tel.: +44 28 90 632638; Fax: +44 28 90 235900; E-mail:
b.mcguinness@qub.ac.uk.
for the diagnostic criteria [3] that were employed in the
present study. Neuropsychological testing informs the
diagnosis of MCI and can assist in delineating specific
MCI subtypes. This is important because individuals
with amnestic multidomain (AMD) MCI have repeat-
edly been shown to have a poorer prognosis due to their
increased risk for dementia [4–6].
A biomarker to complement the clinical and neu-
ropsychological assessment of individuals with MCI
and to assess their risk of conversion to dementia
would be extremely useful [7]. The neuropathologi-
cal changes present in amnestic MCI are similar to
those found in AD, with extracellular cortical plaques
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composed of amyloid- peptides (A) and intracellu-
lar tangles of abnormally phosphorylated tau [8–10].
The most promising biochemical biomarker combina-
tion for the prediction of Alzheimer’s disease (AD)
in amnestic MCI patients is the measurement of
cerebrospinal fluid (CSF) markers of AD pathology,
namely A42 peptide, total-tau, and phospho-tau lev-
els [11]. However, the use of CSF biomarkers is limited
by the invasive nature of lumbar puncture and a blood-
based biomarker would therefore be more useful in a
routine clinical setting.
The beta-site amyloid- protein precursor (APP)
cleaving enzymes 1 and 2 (BACE1 and BACE2,
referred to collectively as BACE in this paper) cat-
alyze the rate-limiting step in A peptide production,
cleaving APP at the -secretase site to generate the
N-terminus of A. Our group and others have reported
altered levels of BACE and -secretase activity in
platelets from individuals with AD [12–14]. We iden-
tified a significant 17% increase in platelet membrane
-secretase activity in AD, which did not correlate with
Mini-Mental State Examination (MMSE) score, indi-
cating that this increase did not occur as a secondary
result of the disease process and may have preceded
symptom onset [14]. Our small pilot study also found
24% more platelet membrane -secretase activity in
patients with MCI, as compared to controls [15], while
an independent study of a smaller Swedish cohort
using different assays found no significant differences
in platelet - or -secretase activity in control, MCI,
and AD groups [16]. Membrane -secretase activity
was found to be influenced by membrane cholesterol
levels [17–18]. It should be noted that our previous
studies in this area were carried out using a Calbiochem
substrate (MCA-EVKMDAEFK-(DNP)-NH2) based
on the APP wild-type sequence at the -secretase
cleavage site. We therefore refer to this activity as ‘-
secretase’, rather than ‘BACE’ activity, because this
type of assay will detect any protease capable of cleav-
ing this peptide sequence and is not specific for the
detection of BACE activity. The present study utilized
BACE inhibitors to explore whether the observed -
secretase activity arose from BACE, or from other
enzymes capable of cleaving the peptide substrate.
This study examined people who were assessed
and diagnosed with MCI shortly after their entry to
a memory clinic service. Thorough neuropsychologi-
cal evaluation was conducted and blood samples were
taken to enable a cross-sectional baseline study of
membrane -secretase activity and membrane choles-
terol levels in MCI participants and controls. Within the
MCI group, we also analyzed baseline platelet mem-
brane parameters in cognitive subgroups. In addition,
the MCI group was examined longitudinally and we
compared the baseline platelet membrane parameters
in individuals who converted to a diagnosis of AD
within 2 years, with those of individuals with stable
MCI.
MATERIALS AND METHODS
Study subjects
Written informed consent was obtained from all par-
ticipants, and the study was performed in accordance
with local ethical committee procedures (Reference
06/NIR02/55). Individuals with MCI were recruited
from the Belfast City Hospital memory clinic. This
is a dual consultant-led memory service providing
regional diagnosis and treatment; most referrals are
received from general practitioners or other specialists.
Individuals with MCI usually presented with mem-
ory problems but were functionally independent and
scored ≥ 24/30 on the MMSE [19] and 82-88/100
on the Addenbrooke’s Cognitive Examination-Revised
(ACE-R) [20]. Patients were diagnosed with MCI
according to criteria developed by an international
working group on MCI [3]. Patients of both gen-
ders and any age were recruited sequentially as they
presented to the clinic. Those with major depressive
and other severe psychiatric disorders were excluded,
whereas subjects with minor depressive symptoms
and mild anxiety were not. MCI participants were
not treated with cholinesterase inhibitors and they
were not participating in any clinical trial. Controls
were recruited from groups of volunteers or were
spouses of patients. They had no subjective or objective
cognitive complaints and were physically and men-
tally healthy. All controls were thoroughly interviewed
about their physical and mental health prior to inclu-
sion in the study and they were evaluated using the
MMSE [19] and ACE-R [20]. Subjects taking any
psychoactive medication with a possible impact on
cognition (including chronic alcohol or drug abuse)
were excluded.
Neuropsychological evaluation
MCI participants were assessed at a time sepa-
rate from their clinic visit, usually 2-4 weeks later.
The assessment took 45-60 min. As recommended by
the American Academy of Neurology, the neuropsy-
chological evaluations assessed speed and attention,
learning and episodic memory, visuospatial function,
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language, and executive function. Within each cogni-
tive domain, several aspects of function were assessed
using specific tests with demonstrated validity for use
within a population with MCI. Briefly, each subject
was tested using the National Adult Reading Test
(NART) with 50 stimulus words in order to estimate
premorbid intellectual status [21]. Episodic memory
was tested using paired associate learning (PAL) from
the Cambridge neuropsychological test automated
battery (CANTAB: http://www.camcog.com/cantab-
tests.asp) and The New York University immediate
and delayed paragraph recall [22]. An executive clock
drawing task (CLOX 1) [23] was used to assess exec-
utive control, and the Stroop color word test (SCWT)
[24] was used to examine attention and response inhi-
bition. The Hayling sentence completion test [25] was
used to identify executive effects on initiation speed
and response suppression. Color trails A and B [26]
were used to assess speed and attention. Language
was assessed using the two-part controlled oral word
association test (COWAT) [27]. Visuospatial function
was assessed using CLOX 2 [23] and the Brixton spa-
tial anticipation test, designed by Burgess and Shallice
[25]. Functional ability was measured by the disability
assessment in dementia (DAD) [28].
In order to compare control and MCI subjects, stan-
dardized z scores (a statistical measurement of a score’s
relationship to the group mean) adjusted for age and
education were calculated for each participant. To dif-
ferentiate participants with MCI on the basis of the
cognitive domains affected, we set a cut-off for each
test at 1.5 standard deviation (SD) below the control
mean. Designation of this level of impairment as clin-
ically significant was consistent with previous studies
of this type [29–30]. Patients with an impaired result
on at least one test within a cognitive domain were
considered impaired in that domain. MCI participants
were then assigned to one of five groups: no impair-
ment of clinical significance (NICS), for individuals
who were < 1.5 SD below the control mean for all tests;
amnestic single domain (ASD); AMD; non-amnestic
single domain (NASD); and non-AMD (NAMD).
Follow-up
Control subjects were assessed once at baseline
and participants with MCI were followed-up annually.
The major objective of the follow-up examination was
to determine the diagnostic status of the participants
(stable MCI, AD, or improved to normal). Diagno-
sis of AD was based on NINCDS-ADRDA criteria
[31]. Those who developed AD were commenced on
a cholinesterase inhibitor, if appropriate, and left the
study.
Preparation of platelet membrane fractions
Whole venous blood (20 mL) was collected in
tubes containing ethylenediaminetetraacetic acid and
centrifuged (150 g, no brake) for 15 min at room tem-
perature. The platelet-rich plasma supernatant was
removed and four volumes of phosphate-buffered
saline (PBS; 137 mM NaCl, 2.7 mM KCl, and 10 mM
phosphate buffer, pH 7.4) were added. Platelets were
recovered by centrifugation (800 g, 5 min); the pellet
was suspended in 4 mL PBS and centrifuged (800 g,
5 min) to obtain a platelet pellet. Platelet pellets were
suspended in 1 mL cell lysis buffer (25 mM HEPES
[Sigma], pH 7.2) and incubated on ice for 1 h before
homogenization by 25-30 strokes of a hand-held safe
seal 5-mL homogenizer (Glass Precision Engineering
Ltd., Leighton Buzzard, UK) followed by centrifu-
gation (100,000 g) for 1 h at 4◦C. The supernatant
(cytosolic fraction) was removed and the remaining
pellet was suspended in 200L membrane solubi-
lization buffer (25 mM HEPES containing 2% [w/v]
CHAPS, Sigma) prior to centrifugation (20,000 g) for
10 min at 4◦C. The resulting supernatant (total mem-
brane fraction) was stored at –80◦C. Sample protein
determinations were carried out using a BCA Protein
Assay Kit (Pierce, Rockford, IL, USA).
β-secretase activity assay
-secretase activity was measured using a
commercially-available fluorogenic substrate, MCA-
SEVNLDAEFR(DNP)KRR-NH2 (Sigma A1472
or Bachem M2465), corresponding to the APP
sequence at the Swedish mutant -secretase site,
derivatized at its N-terminus with a fluorescent
7-methoxy-4-yl acetyl group (MCA), and at its
C-terminus with a 2, 4-dinitrophenyl group (DNP).
MCA fluorescence was internally quenched by DNP
in the intact peptide, and was detected when the
substrate was cleaved. Assays were performed in
96-well black plates and fluorescence was detected
using a BMG Labtech FLUOstar OPTIMA (excitation
330 nm, emission 390 nm). For the pilot studies,
recombinant human BACE1 was obtained from
R&D Systems (931-AS) and native cathepsin D was
obtained from Sigma (C8696). Two inhibitors were
obtained from Calbiochem; product number 171601
(-secretase inhibitor; KTEETSEVN(stat)VAEF)
is referred to as Cal 1 in this study, and product
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number 565788 (-secretase inhibitor IV; a cell-
permeable isophthalamide compound containing an
hydroxyethylamine motif that binds to BACE1) is
referred to as Cal 4.Pilot research investigating the
inhibitory profiles of Cal 1 and Cal 4 under our assay
conditions showed that they both inhibited the activity
of recombinant BACE1, with half-maximal inhibition
at concentrations of 100–200 nM (data not shown).
However, these inhibitors also affected the activity
of cathepsin D, another aspartyl protease potentially
present in the platelet membrane preparations. Cal
1 (100 nM) produced > 90% inhibition of native
cathepsin D, while approximately 5M Cal 4 was
required to achieve half-maximal inhibition of this
activity.
For platelet membrane assays, 15g platelet
membrane protein and 5M MCA-SEVNLDAEFR
(DNP)KRR-NH2 were incubated in a final volume of
100L in assay buffer (50 mM sodium actetate, pH
4.5). The amount of membrane solubilization buffer
present in each assay well was standardized at 10L
to ensure that any detergent effects did not influence
the assay results. Each platelet sample was assayed in
duplicate or triplicate under three assay conditions: 1)
in the absence of inhibitor, 2) in the presence of 2M
Cal 1, and 3) in the presence of 1M Cal 4. Our pilot
data indicated that at these concentrations, Cal 1 would
be expected to inhibit BACE and cathepsin D activities
by > 90%, whereas Cal 4 would be expected to inhibit
BACE activity by > 90%, without affecting cathepsin D
activity. Substrate hydrolysis was followed by measur-
ing fluorescence every 120 s at 37◦C. Initial rates were
calculated over the linear phase (typically for 30 min)
and converted to [MCA] liberated using a calibration
curve on the plate, constructed from a dilution series of
7-methoxycoumarin-4-acetic acid (Sigma). The initial
rates were then expressed as pmoles MCA detected per
h perg membrane protein (pmol MCA/h/g protein).
Membrane cholesterol assay
Platelet membrane fraction cholesterol levels were
determined using the Amplex Red Cholesterol Assay
Kit (Invitrogen), according to the manufacturer’s
instructions. Fifty microliters of cholesterol standards
(0–1000 pmol per well) or sample triplicates were
added to 96-well black plates (Greiner). Fifty micro-
liters of working solution (300M Amplex Red
reagent, 2 unit/mL horseradish peroxide, 2 unit/mL
cholesterol oxidase, 0.2 unit/mL cholesterol esterase)
were added. The plate was incubated for 30 min at
37◦C in the dark before measurement of fluorescence
(excitation 560 nm, emission 590 nm; BMG Labtech
FLUOstar OPTIMA). Sample fluorescence was con-
verted to picomoles cholesterol using the standard
curve, and results expressed as picomol cholesterol/ g
protein.
Statistical analysis
Data were analyzed using the Statistical Package
for the Social Sciences Version 17 (SPSS 17) for
Windows (SPSS Inc., Chicago, IL, USA). Data are pre-
sented as mean ± SD. Study group data were compared
using independent Student’s t-tests, analysis of vari-
ance (ANOVA; continuous dependent variables), and
χ2 tests (frequency data). The primary endpoint was
platelet membrane -secretase activity and a power
calculation based on our previous pilot study of MCI
and control subjects [15] indicated that the numbers
recruited in the present study would provide > 90%
power to detect a difference in means of 0.07 using
two-tailed tests with a p-value of < 0.05. The base-
line platelet parameters were analyzed using a receiver
operating characteristic (ROC) curve, to explore their
usefulness in discriminating between the study groups.
RESULTS
Study subjects
Study subject information is presented in Table 1.
There were no significant differences between the
MCI and control groups in terms of age, gender,
years of education, premorbid IQ (as determined by
Table 1
Baseline characteristics of study participants
Control n = 85 MCI n = 97 p
Age (years) 74.6 ± 9.5 72.4 ± 9.3 0.11
Age range 52–94 43–93
Gender (%F:M) 54:46 64:36 0.17
Years of education 11.6 ± 3.2 12.2 ± 2.9 0.15
NART IQ 113.0 ± 8.5 113.9 ± 8.3 0.49
DAD 79.6 ± 2.3 79.6 ± 0.9 0.93
MMSE 29.3 ± 0.8 27.9 ± 1.7 <0.01
ACE-R 92.1 ± 2.9 83.2 ± 8.7 <0.01
Data provided are mean ± SD. There were no significant differences
in age, gender, years of education, premorbid IQ (National Adult
Reading Test; NART) or activities of daily living (disability assess-
ment in dementia; DAD) in the two study groups. The mild cognitive
impairment (MCI) group had significantly lower scores in the Mini-
Mental State Examination (MMSE) and Addenbrooke’s Cognitive
Examination-Revised (ACE-R), as compared with controls. p-values
are indicated for the comparison between the MCI and control groups
by unpaired t-test (significant p-values are shown in bold).
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NART), or daily function (measured by DAD). The
MCI group had significantly lower MMSE and ACE-R
scores than the control group. Two of the MCI partici-
pants had insufficient neuropsychological data to allow
assignment to a neurocognitive domain subgroup. With
respect to the remaining 95 MCI participants, 46%
were assigned to the AMD subgroup (n = 44), 18%
to the NASD group (n = 17), 22% to the NICS group
(n = 21), 7% to the ASD group (n = 7), and 6% to
the NAMD group (n = 6). MCI patients were followed
for 531.3 ± 308.6 (mean ± SD) days, with a median
follow-up of 510 days (interquartile range 303–774
days). The minimum follow-up period for the subjects
included in the present study was 1 year (for subjects
who had converted to AD at 1 year and therefore left
the study).
Figure 1 details participant flow through the study.
Seven of the 97 MCI participants improved to nor-
mal during the two-year follow-up period. Clinical
follow-up data was unavailable for 9 MCI partici-
pants and these individuals were therefore excluded
from further analyses; a participant diagnosed with
VaD was also excluded. Thirty individuals had con-
verted to a diagnosis of AD by the end of year 2
and 50 individuals had stable MCI. The annual con-
version rate to dementia was 15.7% per year. There
was no significant difference in gender between sta-
ble MCI and AD converters. Those who converted
to AD were significantly older and had a lower
MMSE at baseline than those who remained stable
(Table 2).
Platelet membrane β-secretase activity at baseline
Platelet membrane -secretase activity data are pre-
sented in Table 3 as the mean initial rate in the absence
of inhibitor (total activity); mean initial rates in the
presence of 2M Cal 1 or 1M Cal 4; and the activ-
ity that was inhibited by each inhibitor (total activity
minus the initial rate in the presence of inhibitor).
Although all platelet membrane -secretase activi-
ties tended to be slightly higher in the MCI group
(103–114% of control values), there were no statis-
tically significant differences between the groups. As
noted previously, there were large inter-individual dif-
ferences in activity within the study groups [14]. There
was no statistically significant relationship between
platelet membrane -secretase activity and age or
MMSE.
We also subtracted the initial rate observed in the
presence of Cal 1 from that observed in the presence
MCI par?cipants 
n=97
Stable MCI n=50 AD diagnosis n=30
No clinical follow-
up n=9
Improved to 
normal n=7
VaD n=1
Fig. 1. Participant flow through the study. MCI, mild cognitive
impairment; VaD, vascular dementia; AD, Alzheimer’s disease
Table 2
Baseline characteristics of study participants who remained stable
or converted to Alzheimer’s disease (AD)
Stable MCI Converted to AD p
n = 50 n = 30
Age 70.1 ± 9.9 77.2 ± 5.6 <0.01
MMSE 28.3 ± 1.65 27.0 ± 1.4 <0.01
Gender (%F:M) 60:40 77:23 0.10
Data provided are mean ± SD. The study subjects who converted
to AD were significantly older and had significantly lower Mini-
Mental State Examination (MMSE) scores at baseline. p-values
are indicated for the comparison between the MCI and con-
trol groups by unpaired t-test (significant p-values are shown in
bold).
of Cal 4 to provide a measure of the activity of enzymes
other than BACE that were inhibited by Cal 1 (for
example, cathepsin D). This activity showed no signif-
icant difference between the study groups (0.15 ± 0.1
pmol MCA/h/g protein in both the MCI and control
group).
Platelet membrane -secretase activity was com-
pared across the MCI cognitive sub-groups. No
significant differences in activity were seen between
the MCI subgroups represented in this study, as illus-
trated in Table 4.
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Table 3
Platelet membrane -secretase activity
Initial rate (pmol MCA/h/ g)
Inhibition Control MCI p
(n = 85) (n = 97)
No inhibitor 0.74 ± 0.39 0.81 ± 0.55 0.30
Cal 1 (2M) 0.45 ± 0.30 0.51 ± 0.33 0.22
Cal 4 (1M) 0.60 ± 0.31 0.65 ± 0.42 0.32
Inhibited activity
No inhibitor - 2M Cal 1 0.29 ± 0.17 0.30 ± 0.32 0.69
No inhibitor - 1M Cal 4 0.14 ± 0.10 0.16 ± 0.19 0.41
Platelet membrane fractions were assayed in duplicate or triplicate,
as described in the Methods section: in the absence of inhibitor, in the
presence of 2M Cal 1, or in the presence of 1M Cal 4. Data are
presented as mean initial rate ± SD under the conditions indicated.
The inhibited activity data provides the difference between the ini-
tial rates under the indicated conditions. p-values are indicated for
the comparison between the mild cognitive impairment (MCI) and
control groups by unpaired t-test with Welch’s correction (because
the variances differed significantly).
Platelet membrane cholesterol levels and
β-secretase/cholesterol ratios at baseline
The data presented in Table 5 indicated that platelet
membrane cholesterol was 12% lower in the MCI
group (unpaired t-test, p = 0.01). For each individual,
the ratio of membrane -secretase activity to mem-
brane cholesterol level was then calculated (Table 5).
In the MCI group, the mean ratio of total membrane
-secretase activity to membrane cholesterol level was
124% of that observed in the control group and this dif-
ference was statistically significant (p = 0.02, unpaired
t-test).
We explored whether this difference could be
attributed to BACE activity by calculating the ratio of
the portion of enzyme assay activity inhibited by Cal
1 or Cal 4 to the corresponding membrane cholesterol
level. These data are presented in Table 5. Interestingly,
the ratios of the Cal 1- or Cal 4-inhibited activities
to membrane cholesterol did not differ significantly
between the study groups. However, the ratios of the
initial rates recorded in the presence of either Cal 1 or
Cal 4 (i.e., the activity that was not inhibited by these
BACE inhibitors) to membrane cholesterol did show
significant differences between the groups. These MCI
group values were 131% (Cal 1) or 125% (Cal 4) that
of the control values (p = 0.01 for both comparisons,
unpaired t-test).
The ratio of total membrane -secretase activity to
membrane cholesterol produced a ROC AUC of 0.63
(p = 0.004). Similarly, the ROC AUC of the Cal 1-
uninhibited activity/membrane cholesterol ratio was
0.64 (p = 0.001). ROC analyses of platelet membrane
-secretase activity measures alone produced a maxi-
mum AUC of 0.56 (for the initial rate in the presence of
Cal 1; p = 0.17). Membrane cholesterol alone produced
a ROC curve AUC of 0.60 (p = 0.02).
Baseline platelet membrane parameters and
prognosis
Table 6 shows the mean platelet membrane param-
eters for the sub-groups of individuals with MCI who
remained stable or converted to AD. Analyses of total
-secretase activity, membrane cholesterol, and the
ratio between them showed no significant differences
in the stable MCI group, as compared with the AD
group. However, -secretase activity in the presence
of Cal 1 was significantly different in these groups, as
was the ratio of this activity to membrane cholesterol;
ROC analyses of these measures produced AUCs of
0.63 (p = 0.06) and 0.64 (p = 0.04), respectively. None
Table 4
Platelet membrane -secretase activity in mild cognitive impairment (MCI) subgroups
Initial rate (pmol MCA/h/ g)
Inhibition NICS ASD AMD NASD NAMD ANOVA
n = 21 n = 7 n = 44 n = 17 n = 6 p
No inhibitor 0.97 ± 0.83 0.85 ± 0.37 0.78 ± 0.49 0.79 ± 0.49 0.62 ± 0.25 0.13
Cal 1 (2M) 0.63 ± 0.51 0.59 ± 0.30 0.45 ± 0.24 0.54 ± 0.25 0.48 ± 0.12 0.28
Cal 4 (1M) 0.80 ± 0.66 0.72 ± 0.31 0.61 ± 0.32 0.66 ± 0.30 0.51 ± 0.21 0.41
Inhibited activity
No inhibitor – 2M Cal 1 0.34 ± 0.34 0.25 ± 0.10 0.33 ± 0.38 0.25 ± 0.14 0.21 ± 0.09 0.78
No inhibitor –1M Cal 4
0.17 ± 0.19 0.13 ± 0.07 0.17 ± 0.24 0.13 ± 0.07 0.11 ± 0.05 0.53
Individuals were categorized into MCI subgroups as described in the Methods section: NICS, no impairment of clinical significance; ASD,
amnestic single domain; AMD, amnestic multiple domain; NASD, non-amnestic single domain; and NAMD, non-amnestic multiple domain.
Platelet membrane fractions were assayed in duplicate or triplicate: in the absence of inhibitor, in the presence of 2M Cal 1, or in the presence
of 1M Cal 4. Data are presented as mean initial rate ± SD under the conditions indicated. The inhibited activity data provides the difference
between the initial rates under the indicated conditions. p-values are indicated for the comparison between the subgroups by analysis of variance
(ANOVA).
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Table 5
Platelet membrane cholesterol and -secretase activity
Control n = 84 MCI n = 89 p
Membrane cholesterol (pmol/ g protein) 269.8 ± 86.3 237.5 ± 80.0 0.01
Total initial rate/membrane cholesterol 2.97 ± 1.8 3.68 ± 2.1 0.02
Initial rate with 2M Cal 1/membrane cholesterol 1.83 ± 1.3 2.39 ± 1.5 0.01
(No inhibitor- 2M Cal 1) initial rate/membrane cholesterol 1.15 ± 0.89 1.29 ± 1.0 0.31
Initial rate with 1M Cal 4/membrane cholesterol 2.40 ± 1.4 3.00 ± 1.7 0.01
(No inhibitor- 1M Cal 4) initial rate/membrane cholesterol 0.58 ± 0.5 0.68 ± 0.6 0.23
Platelet membrane fractions were assayed in triplicate for cholesterol and in duplicate or triplicate for enzyme activity, as described in the
Methods section: in the absence of inhibitor, in the presence of 2M Cal 1, or in the presence of 1M Cal 4. Data are presented as the
mean ± SD of the mean initial rate/mean membrane cholesterol level for each individual (multiplied by 1000). p-values are indicated for the
comparison between the mild cognitive impairment (MCI) and control groups by unpaired t-test (significant p-values are shown in bold).
Table 6
Predictive value of baseline platelet measures.
Stable MCI n = 50 Converted to AD AUC (p) n = 30 p ROC AUC (p)
Membrane cholesterol (pmol/g protein) 239.2 ± 77.6 240.5 ± 85.5 0.95
Total initial rate (no inhibitor) 0.90 ± 0.61 0.77 ± 0.52 0.34
Initial rate with Cal 1 (2M) 0.59 ± 0.40 0.42 ± 0.19 0.01# 0.63 (0.06)
Initial rate with Cal 4 (1M) 0.74 ± 0.50 0.58 ± 0.27 0.06# 0.59 (0.19)
Inhibited activity
No inhibitor - 2M Cal 1 0.31 ± 0.25 0.34 ± 0.46 0.68#
No inhibitor - 1M Cal 4 0.15 ± 0.14 0.19 ± 0.29 0.56#
Data obtained from analyses of baseline blood samples in the mild cognitive impairment (MCI) group were sub-divided depending on whether
the individual remained stable or was diagnosed with Alzheimer’s disease (AD) over the subsequent 2 years. Seven individuals who became
cognitively normal within the same time period were omitted from this analysis. Platelet membrane fractions were assayed in triplicate for
cholesterol and in duplicate or triplicate for enzyme activity, as described in the Methods section: in the absence of inhibitor, in the presence of
2M Cal 1, or in the presence of 1M Cal 4. Data are presented as the mean ± SD. p-values are indicated for the comparison between the stable
MCI and AD group, unpaired t-test (#with Welch’s correction where variances differed significantly). ROC, receiver operating characteristic;
AUC, area under the curve.
of the other measures produced statistically significant
results in this respect (Table 6).
DISCUSSION
This study extended our previous work relating to
platelet membrane-secretase activity in MCI and AD
by exploring whether similar effects were observed
with a different -secretase substrate, in the presence
and absence of BACE inhibitors, in a longitudinal study
of a well-characterized group of individuals with MCI.
The current study found that total enzyme activity
measured using the -secretase activity assay tended
to be 10% higher in platelet membranes from MCI
participants, as compared to controls, but this differ-
ence was not statistically significant. This contrasted
with our earlier pilot study where platelet membrane
-secretase activity was determined using a different
BACE substrate (MCA-EVKMDAEFK-(DNP)-NH2)
and found to be 24% higher in MCI participants than
in controls (p = 0.001) [15]. In addition to the differ-
ent -secretase assay employed, we included greater
numbers of MCI participants (n = 97) and controls
(n = 85) in the present study, as compared to the pre-
vious one (52 MCI and 75 controls), and they were
all characterized much more thoroughly from a neu-
ropsychological perspective. One previous study also
reported that platelet -secretase activity was not ele-
vated in MCI [16]. However, only 6 MCI participants
were assessed in this study, alongside 30 healthy con-
trols and 20 participants with probable AD. Different
platelet preparation and -secretase assay methods
were used and the demographics of the sample pop-
ulations also differed, making it difficult to compare
these studies directly. A more recent study enrolled 34
ASD MCI participants, 45 AD patients, and 28 con-
trols and assayed platelet -secretase activity using
a Calbiochem substrate with the Swedish mutation
sequence. This identified significantly increased activ-
ity in the MCI and AD groups, as compared to
age-matched controls (1.9- and 1.5-fold change respec-
tively), with no significant difference between the MCI
and AD groups [32].
These previous platelet -secretase studies did not
employ inhibitors to explore the specificity of the
assay signal obtained. The present study investigated
the assay signal further by measuring activity in the
presence and absence of two BACE inhibitors. This
provided a more specific measure of enzyme activ-
ity, although this approach was still imperfect due the
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lack of inhibitor specificity. For example, our pilot data
indicated that cathepsin D, another aspartyl protease
likely to be present in platelet membrane prepara-
tions, cleaved the substrate and was also inhibited by
the BACE inhibitors to different extents. It is clear
that other proteases capable of cleaving this substrate
(and the wild-type substrate employed previously) may
also be present in the platelet membrane prepara-
tions. We therefore referred to the activity reported in
this and previous publications as ‘-secretase’, rather
than ‘BACE’, activity. Development of extremely spe-
cific non-peptidic BACE1 inhibitors that can block the
enzyme activity in complex samples, such as brain
lysates, may facilitate more specific measurement of
BACE1 activity in the future [33]. Nonetheless, all of
the-secretase activity measured in assays like the one
employed in the present study may be biologically rel-
evant, and the possibility of cathepsin D contributing
to platelet -secretase activity along with BACE1 has
been raised in a review of the relevant literature [33].
Platelet membrane cholesterol levels were signifi-
cantly lower in the MCI group than in the control group.
This was consistent with our previous report that cog-
nitively impaired participants (with AD and MCI) had
18% lower membrane cholesterol levels than the con-
trol group [18]. The present study found that the ratio of
total membrane-secretase activity/membrane choles-
terol was significantly elevated in the MCI group, even
though the different study subject groups (MCI versus
MCI plus AD) and-secretase assays employed meant
that itwasnotpossible tocompare thesestudiesdirectly.
Interestingly, the use of inhibitors enabled us to deter-
mine that there was no significant difference between
the ratio of ‘specific’ BACE activity (no inhibitor – the
Cal1orCal4initial rates) tomembranecholesterol level
in the MCI and control groups. However, the initial rate
in the presence of Cal 1 or Cal 4/membrane cholesterol
level showed the most significant differences between
the study groups (31% or 24% higher in the MCI group,
respectively,p = 0.01forboth); thesemeasuresreflected
a difference in a -secretase-like activity that was not
inhibited by the BACE inhibitors.
It is likely that disease-modifying treatments for
AD need to be initiated before overt symptoms are
apparent, as these functional changes reflect severe
and currently irreversible neurodegenerative changes.
A method to identify those at heightened risk for AD
in the future is therefore urgently required so that
novel therapies can be targeted effectively. Using the
longitudinal clinical data, we explored whether the
baseline platelet measures could help to identify indi-
viduals within the MCI group who would subsequently
develop AD. We found that the -secretase assay ini-
tial rate in the presence of Cal 1 was significantly
(40%) higher in the stable MCI group, and use of
the ratio between this enzyme activity and membrane
cholesterol produced a ROC AUC of 0.64 (p = 0.04).
Although this value indicated that this individual test
was a poor discriminator of individuals who would
convert from MCI to AD within 2 years, further refine-
ment may enable it to contribute to a prognostic battery
used to inform treatment decisions.
Further biochemical analyses with the aim of iden-
tifying the source of the enzyme activity measured
under these assay conditions would be very valuable
as they may help to improve the specificity of this
measurement. Although the MCI versus control group
comparisons revealed higher levels of enzyme activ-
ity and activity/cholesterol ratios in the MCI group as
a whole, those MCI subjects who subsequently con-
verted to AD actually had lower levels of enzyme
activity and activity/cholesterol ratios than those who
remained stable. Any speculation about the signifi-
cance of this is difficult, given the lack of data in the
area; however, it is possible that these platelet parame-
ters and the relationships between them fluctuate over
the course of the disease.
These findings indicated that further research into
the source of the difference in platelet membrane
-secretase activity in individuals with stable MCI
and those who converted to AD has the potential to
contribute to the identification of patients who are
at increased risk for dementia. The development of
prognostic instruments combining neuropsychological
information with platelet biochemical measures and
known genetic risk factors may facilitate effective tar-
geting of future disease-modifying therapies for AD.
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